Lataa...
The cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains
Bromodomain-containing proteins are considered atypical kinases, but their potential to interact with kinase inhibitors is unknown. Dinaciclib is a potent inhibitor of cyclin-dependent kinases (CDKs) which recently advanced to Phase III clinical trials for the treatment of leukemia. We determined th...
Tallennettuna:
| Päätekijät: | , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2013
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3846258/ https://ncbi.nlm.nih.gov/pubmed/24007471 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/cb4003283 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|